• PSU21 THE REUSE OF SINGLE-USE SURGICAL DEVICES- EVALUATION OF THE ECONOMIC EVIDENCE

    May 1, 2011, 00:00

  • PMD29 PATIENT TIME AND INDIRECT COSTS ASSOCIATED WITH SENSOR-AUGMENTED INSULIN PUMP THERAPY IN TYPE 1 DIABETES

    May 1, 2011, 00:00

  • PMH81 RELATIONSHIP BETWEEN ADHERENCE TO ANTIDEPRESSANT TREATMENTS AND DEPRESSIVE RELAPSE

    May 1, 2011, 00:00

  • PIN20 A COST BENEFIT ANALYSIS OF ANTI-RETROVIRAL (ARVS) DRUGS IN THE TREATMENT OF HIV IN UGANDA

    May 1, 2011, 00:00

  • PIN1 VACCINE-ASSOCIATED GUILLAIN-BARRE SYNDROME- A PHARMACOVIGILANCE ANALYSIS OF DATA IN THE UNITED STATES' VACCINE ADVERSE EVENT REPORTING SYSTEM (1990-2009)

    May 1, 2011, 00:00

  • PCV47 COST-EFFECTIVENESS OF FONDAPARINUX AND ENOXAPARIN IN PATIENTS WITH NON ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IN BRAZIL

    May 1, 2011, 00:00

  • PRM7 DRUG DEVELOPMENT AND PHARMACEUTICAL PRICING IN THE UNITED STATES- THE INFLUENCE OF DRUG INTENDED OUTCOMES OF DRUG PRICING

    May 1, 2011, 00:00

  • PRS7 USE OF INHALED TOBRAMYCIN IS ASSOCIATED WITH REDUCED MORTALITY IN PATIENTS WITH CYSTIC FIBROSIS

    May 1, 2011, 00:00

  • PCN33 COST SAVINGS ASSOCIATED WITH TRANSFUSION INDEPENDENCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME WITH A 5Q- DELETION

    May 1, 2011, 00:00

  • PIH14 PROJECTING THE POTENTIAL COST-EFFECTIVENESS OF UNIVERSAL ACCESS TO MODERN CONTRACEPTIVES IN UGANDA

    May 1, 2011, 00:00

  • PDB9 IMPACT OF EXENATIDE, PEN INSULIN AND VIAL/SYRINGE INSULIN ON PATIENT OUTCOMES IN A DIABETES POPULATION IN THE UNITED STATES- A RETROSPECTIVE DATABASE ANALYSIS OF PERSISTENCE AND FIRST-YEAR COSTS

    May 1, 2011, 00:00

  • PMH79 PSYCHOTROPIC POLYPHARMACY IN CHILDREN AND ADOLESCENTS WITH ATTENTION – DEFICIT / HYPERACTIVITY DISORDER

    May 1, 2011, 00:00

  • PND31 HEADACHE DAY HEALTH STATES AND TRANSITION PROBABILITIES FOR PATIENTS WITH CHRONIC MIGRAINE WITH AND WITHOUT HEADACHE PROPHYLAXIS

    May 1, 2011, 00:00

  • PHP64 THE RELATIONSHIP BETWEEN FINANCIAL IMPACT AND THE LIKELIHOOD OF DRUG REIMBURSEMENT IN THE AUSTRALIAN HEALTH CARE SYSTEM

    May 1, 2011, 00:00

  • PSY15 COSTS OF CARE FOR PRIVATELY INSURED MALES WITH HEMOPHILIA IN THE UNITED STATES, 2008

    May 1, 2011, 00:00

  • PHP104 CURRENT USES OF AND PERCEPTIONS ABOUT FDAMA SECTION 114

    May 1, 2011, 00:00

  • PHP36 CATASTROPHIC INJURY-RELATED ENROLLMENT AND COSTS IN A STATE MEDICAID FEE-FOR-SERVICE PROGRAM

    May 1, 2011, 00:00

  • PMH18 IMPACT OF COGNITIVE IMPAIRMENT ON FUNCTIONING, MEDICAL RESOURCE UTILIZATION, ADHERENCE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA

    May 1, 2011, 00:00

  • PSY9 HEALTH CONSEQUENCES AND COSTS OF TACHOSIL® AS HAEMOSTATIC TREATMENT IN LIVER SURGERY VERSUS TISSUCOL®- A RETROSPECTIVE OBSERVATIONAL COHORT STUDY

    May 1, 2011, 00:00

  • PIN28 ESTIMATED HEALTH AND ECONOMIC IMPACT OF QUADRIVALENT HPV TYPES 6, 11, 16, 18 VACCINE IN BRAZIL USING A TRANSMISSION DYNAMIC MODEL

    May 1, 2011, 00:00

  • PND4 DIAGNOSIS OF SHIFT WORK DISORDER AND THE IMPACT OF EXCESSIVE SLEEPINESS- RESULTS FROM SHIFT WORKERS, PATIENTS WITH SHIFT WORK DISORDER, AND HEALTH CARE PROFESSIONALS PARTICIPATING IN AN INTERNET SURVEY

    May 1, 2011, 00:00

  • PIN38 RIGHT IMMUNIZATION DOSES RECEIVED BY PEDIATRIC YOUNGER THAN 2 YEARS

    May 1, 2011, 00:00

  • PSY17 A PHARMACOECONOMIC EVALUATION OF ROMIPLOSTIM (NPLATE®) FOR THE TREATMENT OF CHRONIC IMMUNE THROMBOCYTOPENIA (ITP) IN MEXICO

    May 1, 2011, 00:00

  • PSY44 PAIN MANAGEMENT- IMPACT ON QUALITY OF LIFE

    May 1, 2011, 00:00

  • PCN68 AN ECONOMIC EVALUATION OF DASATINIB FOR THE TREATMENT OF IMATINIB REISTANT PATIENTS WITH CHRONIC MYELOGENOUS LEUKAEMIA

    May 1, 2011, 00:00

  • PMS23 COST-EFFECTIVENESS ANALYSIS OF ANALGESIC THERAPY FOR POSTOPERATIVE PAIN AFTER TOTAL HIP ARTHROPLASTY IN MEXICO

    May 1, 2011, 00:00

  • PCV111 IDENTIFICATION OF RESPONSE SHIFT AMONG HYPERTENSIVE PATIENTS WITH CORONARY ARTERY DISEASE USING TWO STRUCTURAL EQUATION MODELING TECHNIQUES

    May 1, 2011, 00:00

  • PDB11 COMPARISON OF MULTIVARIABLE-ADJUSTED LOGISTIC REGRESSION WITH PROPENSITY SCORE-MATCHED, PROPENSITY SCORE-STRATIFIED, AND PROPENSITY SCORE-ADJUSTED LOGISTIC REGRESSION MODELS

    May 1, 2011, 00:00

  • PCN58 IS CYP2D6 GENETIC TEST IN COMBINATION WITH HORMONE THERAPY FOR ER+ HORMONE SENSITIVE WOMEN WITH EARLY BREAST CANCER COST-EFFECTIVE?

    May 1, 2011, 00:00

  • PSY67 REASONS FOR INITIATING INTRAVENOUS BIOLOGIC THERAPY AMONG PATIENTS WITH IMMUNOLOGY CONDITIONS- SUBSET ANALYSIS OF PRIOR SUBCUTANEOUS INJECTION (SQ) USERS AND IMPLICATIONS FOR SHARED DECISION MAKING

    May 1, 2011, 00:00

  • PRS9 COMPARISON OF THE BURDEN AND COST DRIVERS OF COPD HOSPITALIZATION BETWEEN HISPANIC AND WHITE POPULATION IN THE UNITED STATES

    May 1, 2011, 00:00

  • PRS12 A NATIONAL SURVEY OF SOCIETAL COST OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE IN SOUTH KOREA

    May 1, 2011, 00:00

  • PSY25 RELATIONSHIP BETWEEN MONTHLY OUT-OF-POCKET HEALTHCARE COSTS AND WORK PRODUCTIVITY AMONG PATIENTS WITH INFLAMMATORY BOWEL DISEASE

    May 1, 2011, 00:00

  • PHP41 THE CHANGING LANDSCAPE OF ORPHAN DRUG PROVISION IN THE EU5 AND THE UNITED STATES

    May 1, 2011, 00:00

  • PMS26 COST-EFFECTIVENESS MODELING IN OSTEOPOROSIS- A SYSTEMATIC LITERATURE REVIEW AND OVERVIEW

    May 1, 2011, 00:00

  • PMH66 MULTIMORBIDITY AND DEPRESSION TREATMENT

    May 1, 2011, 00:00

  • PIN40 DO PATIENTS AND PHYSICIANS HAVE SIMILAR PREFERENCES FOR HEALTH CARE DECISIONS INVOLVING UNCERTAIN OUTCOMES FOR CHRONIC HEPATITIS B IN GERMANY AND TURKEY?

    May 1, 2011, 00:00

  • PCV35 COMPARISON OF MAJOR BLEEDING RELATED MORTALITY, HEALTH CARE UTILIZATION AND COSTS OF PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • PMH4 RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING ATYPICAL ANTIPSYCHOTICS-A MULTIPLE PROPENSTY SCORE ADJUSTED RETROSPECTIVE COHORT STUDY

    May 1, 2011, 00:00

  • PSY66 BIOLOGIC EXPERIENCE AND DOSING OF GOLIMUMAB PATIENTS IN MANAGED CARE

    May 1, 2011, 00:00

  • PSS17 THE EFFECT OF ORAL CP-690,550 ON PRURITUS IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS

    May 1, 2011, 00:00

  • PIN8 EPIDEMIOLOGY OF METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS AT A MIDWESTERN ACADEMIC HEALTH CARE CENTER

    May 1, 2011, 00:00

  • PSY52 POTENTIAL DRUG-DRUG INTERACTIONS (DDIS) WITH PAIN MEDICATIONS AMONG PATIENTS WITH BACK AND NECK PAIN DIAGNOSES CATEGORIZED INTO NOCICEPTIVE, NEUROPATHIC OR MIXED PAIN COHORTS

    May 1, 2011, 00:00

  • PND48 MEASUREMENT CHARACTERISTICS OF THE SF-36 IN CHRONIC NEUROMUSCULAR DISORDER

    May 1, 2011, 00:00

  • PUK6 LOW-MOLECULAR-WEIGHT HEPARIN IN CHRONIC HEMODIALYSIS PATIENTS- A SYSTEMATIC REVIEW AND META-ANALYSIS

    May 1, 2011, 00:00

  • PRS25 FACTORS INFLUENCING SATISFACTION WITH COPD MAINTENANCE MEDICATION- CONCEPTS ELICITED THROUGH QUALITATIVE INTERVIEWS WITH PATIENTS

    May 1, 2011, 00:00

  • OR2 ASSESSING THE RELATIONSHIP BETWEEN MEDICATION ADHERENCE AND EMPLOYEE PRODUCTIVITY

    May 1, 2011, 00:00

  • PSY75 PREVALENCE RATIOS AGAINST ODDS RATIOS AS EFFECT MEASURES IN A CROSS-SECTIONAL STUDY OF OBESITY AND ITS CHRONIC COMORBID CONDITIONS

    May 1, 2011, 00:00

  • PCV103 PHARMACIST INTERVENTIONS WITHIN A COMMUNITY PHYSICIAN BASED MEDICAL HOME PRACTICE- DIABETES CLINICAL OUTCOMES

    May 1, 2011, 00:00

  • PMD27 COST-MINIMIZATION ANALYSIS OF BIOPSY-BASED RISK STRATIFICATION TOOLS IN INTERMEDIATE AND HIGH RISK PROSTATE CANCER PATIENTS BASED ON RESULTS FROM PHYSICIAN CASE STUDIES

    May 1, 2011, 00:00

  • PIN17 TREATMENT PATTERNS AND DRUG TREATMENT COSTS ASSOCIATED WITH NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI)-BASED ANTIRETROVIRAL THERAPY IN TREATMENT-NAÏVE HIV-1 INFECTED PATIENTS

    May 1, 2011, 00:00

  • PGI24 DOES UTILITY OR CAPABILITY MATTER FOR IRRITABLE BOWEL SYNDROME? - A PRELIMINARY QUALITATIVE STUDY ON TAIWANESE PATIENTS

    May 1, 2011, 00:00

  • PMS48 IMPACT OF ANTI-TNF ON HEALTH CARE UTILIZATION AND COSTS IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ALBERTA, CANADA

    May 1, 2011, 00:00

  • PSS24 MEDICATION CHOICE AND ASSOCIATED HEALTH CARE OUTCOMES AND COSTS FOR PATIENTS WITH ACNE AND ACNE RELATED CONDITIONS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PCN10 ARE FURTHER STUDIES OF BREAST CANCER TUMOR MARKERS TO DETECT RECURRENCE WORTHWHILE? A VALUE OF RESEARCH ANALYSIS

    May 1, 2011, 00:00

  • PND40 ASSESSMENT OF PERCEIVED SEVERITY OF DISEASE AND SYMPTOMS, QUALITY OF LIFE, WORK PRODUCTIVITY, AND HEALTH CARE RESOURCE USE IN INDIVIDUALS WITH MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PSY71 HEALTH AND FUNCTIONAL STATUS FOR INDIVIDUALS WITH THROMBOCYTOPENIA IN THE UNITED STATES- EVIDENCE FROM NHANES

    May 1, 2011, 00:00

  • PMS65 RHEUMATOID ARTHRITIS PATIENT EXPERIENCE WITH SELF-INJECTION WITH SUBCUTANEOUS BIOLOGICS

    May 1, 2011, 00:00

  • PMS68 ANALYSIS OF INFLIXIMAB DOSE CHANGES OVER TIME IN MEDICARE BENEFICIARIES WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PCV58 ASSOCIATION BETWEEN HEART FAILURE AND RESOURCE UTILIZATION IN ST-ELEVATION MYOCARDIAL INFARCTION PATIENTS TREATED WITH PERCUTANEOUS CORONARY INTERVENTION

    May 1, 2011, 00:00

  • PMH42 ECONOMIC EVALUATION OF DESVENLAFAXINE IN THE ACUTE MANAGEMENT OF ASSOCIATED MAJOR DEPRESSIVE DISORDER IN MEDICALLY ILL INPATIENTS FROM A BRAZILIAN PUBLIC GENERAL HOSPITAL PERSPECTIVE

    May 1, 2011, 00:00

  • PMD17 ANALYSIS OF COST DRIVERS IN STRUCTURED SMBG IN POORLY CONTROLLED, NON-INSULIN TREATED TYPE-2 DIABETES- RESULTS FROM THE STEP STUDY

    May 1, 2011, 00:00

  • PCV49 COST-EFFECTIVENESS ANALYSIS OF RIVAROXABAN VERSUS DABIGATRAN AND ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLISM AFTER TOTAL KNEE REPLACEMENT

    May 1, 2011, 00:00

  • PCV70 VARIATIONS IN THE IMPACT OF ILLNESS PERCEPTIONS AND MEDICATION BELIEFS ON MEDICATION COMPLIANCE OF ELDERLY VERSUS GERIATRIC HYPERTENSIVE COHORTS- A COMPARATIVE ANALYSIS

    May 1, 2011, 00:00

  • PRM5 A REVIEW AND CLASSIFICATION OF CONTINGENT VALUATION METHOD STUDIES IN SUB-SAHARA AFRICA

    May 1, 2011, 00:00

  • PSY24 COST-UTILITY ANALYSES OF DIFFERENT ERYTROPOIETINS IN ANEMIC PATIENTS ON DIALYSIS IN RUSSIA

    May 1, 2011, 00:00

  • PND42 THE ASSOCIATION BETWEEN PARKININSON'S DISEASE QUESTIONNAIRE (PDQ) SCORES WITH CARER STRAIN AND QUALITY OF LIFE

    May 1, 2011, 00:00

  • PND55 USE OF TIME-TO-EVENT ANALYSES TO DEFINE EPISODES OF CARE IN SICKLE CELL DISEASE

    May 1, 2011, 00:00

  • PGI8 COMPARING HEALTH-RISK BURDEN, LOST PRODUCTIVITY, AND TOTAL HEALTHCARE COSTS AMONG INDIVIDUALS WITH INFLAMMATORY BOWEL DISEASE AND FIVE MOST PREVALENT CHRONIC DISEASES

    May 1, 2011, 00:00

  • PIH18 THE IMPACT OF LONG-TERM DISABILITY COSTS ARISING FROM IN-VITRO FERTILIZATION (IVF) TREATMENT- THE COST-EFFECTIVENESS ANALYSIS OF REDUCING MULTIPLE BIRTHS

    May 1, 2011, 00:00

  • PHP52 INCREASE IN UNINTENTIONAL FATAL POISONINGS BY NOXIOUS SUBSTANCES IN KANSAS CITY, MISSOURI, FROM 1999 TO 2008

    May 1, 2011, 00:00

  • PMD26 ECONOMIC EVALUATIONS FOR SCREENING AND TREATMENTS OF DIABETIC RETINOPATHY AND DIABETIC MACULAR EDEMA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PMS56 HEALTH CARE UTILIZATION AND PATIENT FINANCIAL BURDEN ANALYSIS OF PRE- VERSUS POST-DIAGNOSIS OF FIBROMYALGIA SYNDROME (FMS)

    May 1, 2011, 00:00

  • PMD15 ECONOMIC EVALUATION OF SELF-MONITORING OF BLOOD GLUCOSE REGIMES PLUS CONVENTIONAL PHARMACOLOGIC TREATMENT FOR TYPE-2 DIABETIC PATIENTS IN MEXICO- ESTIMATION BY DISCRETE EVENT SIMULATION

    May 1, 2011, 00:00

  • PHP42 EVALUATING DRUG COST AND RESTRICTION PROCESSES OF COMMONLY USED PRESCRIPTION DRUGS UNDER EACH 2011 CALIFORNIA STAND-ALONE MEDICARE PART D PLAN

    May 1, 2011, 00:00

  • PRM46 R … YOU AWARE HOW USEFUL IT IS? THE VALUE OF CORRELATION COEFFICIENTS IN META-ANALYSIS

    May 1, 2011, 00:00

  • PCV57 HEALTH CARE RESOURCE UTILIZATION AMONG T2DM PATIENTS WITH PRE-EXISTING MACROVASCULAR CONDITIONS- A MATCHED COHORT STUDY

    May 1, 2011, 00:00

  • EE2 VALIDATION OF THE UPDATED CHARLSON COMORBIDITY INDEX (CCI) TO PREDICT HEALTH CARE UTILIZATION FOR DIABETIC PATIENTS USING ADMINISTRATIVE DATA

    May 1, 2011, 00:00

  • PMH6 DIFFERENTIAL RATES OF SIDE EFFECTS IN DEPRESSED ADULTS AND ADOLESCENTS BEING TREATED WITH ANTIDEPRESSANTS

    May 1, 2011, 00:00

  • PND33 UTILIZING A PAPER STANDARD GAMBLE INSTRUMENT TO ASSESS HEALTH UTILITY IN PATIENTS WITH HEMOPHILIA B

    May 1, 2011, 00:00

  • PCV27 IS ANEMIA ASSOCIATED WITH HEART FAILURE? NHANES DATABASE (2005-2006) ANALYSIS

    May 1, 2011, 00:00

  • PSS15 DEVELOPMENT OF A MULTIATTRIBUTE INSTRUMENT FOR ESTIMATING UTILITIES (PREFERENCE WEIGHTS) IN PEOPLE WITH GLAUCOMA FROM THE NATIONAL EYE INSTITUTE VISUAL FUNCTIONING QUESTIONNAIRE (NEI-VFQ)

    May 1, 2011, 00:00

  • PMS47 EMPLOYABILITY-ADJUSTED-LIFE-YEARS IN PATIENTS WITH RHEUMATOID ARTHRITIS TREATED WITH GOLIMUMAB PLUS METHOTREXATE OR METHOTREXATE ALONE

    May 1, 2011, 00:00

  • PDB45 THE PATIENT REPORTED EXPERIENCE OF LIVING WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN (DPNP)

    May 1, 2011, 00:00

  • PSY63 LONGITUDINAL ANALYSIS OF INFLIXIMAB DOSING AND INFUSION INTERVALS ACROSS 30 INFUSIONS

    May 1, 2011, 00:00

  • PSY4 TRENDS IN HYPONATREMIA MANAGEMENT AND ASSOCIATED OUTCOMES IN HOSPITAL SETTINGS- INTERIM RESULTS FROM AN OBSERVATIONAL, PROSPECTIVE, MULTI-CENTER, GLOBAL REGISTRY IN HOSPITALIZED PATIENTS

    May 1, 2011, 00:00

  • PRM9 PHARMACOECONOMICS IN REPUBLIC OF KAZAKHSTAN

    May 1, 2011, 00:00

  • PHP109 AN OUTCOMES PROFILE REGISTRY FOR ESTABLISHING A BASELINE MATRIX IN COMPARATIVE EFFECTIVENESS STUDIES IN PREDICTIVE PHARMACOLOGY

    May 1, 2011, 00:00

  • PCN103 THE IMPACT OF INFUSION REACTIONS ASSOCIATED WITH MONOCLONAL ANTIBODIES IN METASTATIC COLORECTAL CANCER- A EUROPEAN PERSPECTIVE

    May 1, 2011, 00:00

  • PIH10 HEALTH CARE RESOURCE UTILIZATION AND COSTS IN FEMALES WITH NEWLY DIAGNOSED HEAVY MENSTRUAL BLEEDING- AN EMPLOYER'S PERSPECTIVE

    May 1, 2011, 00:00

  • PMH74 UTILIZATION, PRICE AND SPENDING TRENDS FOR SEROTONIN–NOREPINEPHRINE REUPTAKE INHIBITORS IN THE UNITED STATES MEDICAID PROGRAM- 1991-2009

    May 1, 2011, 00:00

  • PHP96 REASONS FOR REJECTION OF PRO LABEL CLAIMS- AN ANALYSIS BASED ON A REVIEW OF PRO USE AMONG NEW MOLECULAR ENTITIES AND BIOLOGIC LICENSE APPLICATIONS 2006-2010

    May 1, 2011, 00:00

  • PCV67 EXAMINING MEDICATION ADHERENCE AMONG TRICARE BENEFICIARIES RECEIVING STATIN THERAPY FOR SECONDARY PREVENTION OF CORONARY HEART DISEASE IN MILITARY TREATMENT FACILITIES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS32 ECONOMIC EVALUATION OF THE TREATMENT OF RHEUMATOID ARTHRITIS WITH ANTI-TNF BIOLOGICAL THERAPIES IN COLOMBIA

    May 1, 2011, 00:00

  • PCN122 MELODY BRAZIL- CHEMOTHERAPY CHOICES FOR PATIENTS WITH METASTATIC MELANOMA IN THE PUBLIC HEALTH CARE SYSTEM (SUS)

    May 1, 2011, 00:00

  • PMD37 A NATIONAL STUDY OF OUT-OF-POCKET EXPENDITURES FOR MAMMOGRAPHY SCREENING

    May 1, 2011, 00:00

  • PCN77 USE OF SUBSTANCE ABUSE AMONG RESIDENTS OF KARACHI- REASONS AND COST OF USING SUBSTANCES

    May 1, 2011, 00:00

  • PND63 LITTLE OR NO TREATMENT EFFECT? APPLICATION OF GROWTH MIXTURE MODELS TO EXPLORE UNKNOWN SUBGROUPS OF DIFFERENTIAL RESPONDERS TO TREATMENT

    May 1, 2011, 00:00

  • PHP72 ASSESSING THE QUALITY OF PHARMACOECONOMIC STUDIES IN INDIA- A SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PCV79 IMPACT OF DISEASE MANAGEMENT PROGRAM “DE TODO CORAZON” OF MUTUAL SER HMO TO CONTROL CARDIOVASCULAR RISK, COHORT 2004-2009, COLOMBIA

    May 1, 2011, 00:00

  • PMH28 REAL-WORLD HEALTH CARE UTILIZATION AND COSTS IN NEWLY DIAGNOSED DEPRESSION PATIENTS BETWEEN 2006 AND 2008

    May 1, 2011, 00:00

  • PCN55 RACIAL VARIATION IN THE COST-EFFECTIVENESS OF CHEMOTHERAPY FOR PROSTATE CANCER

    May 1, 2011, 00:00

  • PIN26 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF BACTEREMIA AND INFECTIVE ENDOCARDITIS IN PATIENTS WITH METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS INFECTION IN MEXICO

    May 1, 2011, 00:00

  • PCV89 COMPARISON OF DOSING PATTERNS AMONG PATIENTS INITIATING STATIN THERAPY IN A MANAGED CARE POPULATION

    May 1, 2011, 00:00

  • PRM29 METHODOLOGICAL DIFFERENCES IN EQ-5D SCORING SYSTEMS- A SYSTEMATIC REVIEW AND ANALYSIS

    May 1, 2011, 00:00

  • PCN104 HOSPITAL COSTS OF ADVERSE EVENTS IN PATIENTS RECEIVING TREATMENT FOR METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PCN107 PAYER-RATED VALUE OF PAIN IMPROVEMENT IN CASTRATION-RESISTANT PROSTATE CANCER- TRADEOFFS BETWEEN SURVIVAL, PAIN AND ANALGESIC USE

    May 1, 2011, 00:00

  • PCV28 CARDIOVASCULAR RISK FACTORS AMONG CHINESE AND WHITE ADULTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PSY38 PATIENT-REPORTED OUTCOMES IN SUBJECTS WITH PAINFUL DIABETIC PERIPHERAL NEUROPATHY- PAIN DESCRIPTION AND QUALITY OF LIFE

    May 1, 2011, 00:00

  • PCN85 CANCER PATIENTS' PERCEPTION TOWARDS THE USE OF TRADITIONAL CM) FOR CANCER TREATMENT- A QUALITATIVE STUDY

    May 1, 2011, 00:00

  • PSY36 DEVELOPMENT OF THE LUPUS IMPACT TRACKER- A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)

    May 1, 2011, 00:00

  • PDB35 UTILIZATION OF PHYSICIAN, NURSING AND DIETICIAN SERVICES BY TYPE 2 DIABETIC PATIENTS ATTENDING PRIMARY CARE CLINICS IN SINGAPORE

    May 1, 2011, 00:00

  • PSS28 EFFECT OF DIFFERENT RECALL PERIODS ON DRY EYE SYMPTOM RATINGS

    May 1, 2011, 00:00

  • PDB51 IMPROVING HEALTH INSURANCE AND PREVENTIVE EFFORT AMONG DIABETIC PATIENTS- THE COLOMBIAN EXPERIENCE

    May 1, 2011, 00:00

  • PSS12 A DISCRETE EVENT SIMULATION TO OPTIMISE THE ALLOCATION OF CONSTRAINED HOSPITAL RESOURCES FOR GLAUCOMA

    May 1, 2011, 00:00

  • PDB54 USE OF ELECTRONIC MEDICAL RECORDS FOR CLINICAL RESEARCH IN THE MANAGEMENT OF TYPE-2 DIABETES

    May 1, 2011, 00:00

  • PCV25 MANAGEMENT OF ACUTE ISCHEMIC STROKE AND ITS LONG TERM EVOLUTION IN THE UNITED STATES AND CANADA

    May 1, 2011, 00:00

  • PIN29 A COST-EFFECTIVENESS ANALYSIS ON THE USE OF DAPTOMYCIN FOR THE TREATMENT OF SKIN AND SOFT TISSUE INFECTIONS WITH FAILURE TO VANCOMYCIN THERAPY IN MEXICO

    May 1, 2011, 00:00

  • PMH56 COMPARISON OF DIFFERENT COMORBIDITY MEASURES FOR PREDICTING PHYSICAL AND MENTAL HEALTH IN DEMENTIA

    May 1, 2011, 00:00

  • PHP66 DEMONSTRATING “DISEASE MODIFYING THERAPIES”? AN HTA PERSPECTIVE

    May 1, 2011, 00:00

  • PCV97 IS CARDIOVASCULAR MEDICATION USAGE A MARKER FOR CARDIOVASCULAR RISK? POTENTIAL IMPLICATION FOR SMART-EDIT FORMULARY MANAGEMENT STRATEGIES

    May 1, 2011, 00:00

  • PCN113 LEARNING THE LESSONS OF ONCOLOGY HTA REVIEWS IN AUSTRALIA THE UNITED KINGDOM – A CASE STUDY OF FIVE DRUGS

    May 1, 2011, 00:00

  • PMS44 ASSESSING VITALITY IN PATIENTS UNDERGOING ETANERCEPT THERAPY FOR RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PSS25 MEDICATION ADHERENCE TO TOPICAL MEDICATIONS AND HEALTHCARE EXPENDITURES IN MEDICAID-ENROLLED CHILD WITH ATOPIC DERMATITIS

    May 1, 2011, 00:00

  • PMH20 PSYCHOTROPIC MEDICATION USE AMONG CHILDREN WITH AUTISM SPECTRUM DISORDER- A COMPARISON BETWEEN MEDICAID AND COMMERCIAL INSURANCE

    May 1, 2011, 00:00

  • PMS33 COST EFFECTIVENESS OF ABATACEPT IN COMPARISON WITH OTHER BIOLOGIC THERAPIES FOR THE TREATMENT OF MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS PATIENTS WHO HAVE FAILED TO METHOTREXATE BASED TREATMENT AT ESSALUD IN 2010

    May 1, 2011, 00:00

  • PSY33 EXPLORING THE FACTOR STRUCTURE OF THE PROMIS FATIGUE ITEM BANK IN PATIENTS WITH FIBROMYALGIA

    May 1, 2011, 00:00

  • PCN53 RISK OF PERSONAL BANKRUPTCY FOLLOWING A CANCER DIAGOSIS

    May 1, 2011, 00:00

  • PCV51 THE VALUE OF ATORVASTATIN OVER THE PRODUCT LIFE CYCLE

    May 1, 2011, 00:00

  • PMS15 COMPARING HEALTH-RISK BURDEN, LOST PRODUCTIVITY, AND TOTAL HEALTH CARE COSTS AMONG INDIVIDUALS WITH RHEUMATOID ARTHRITIS AND TOP FIVE CHRONIC DISEASES

    May 1, 2011, 00:00

  • PCV100 HEALTH CARE UTILIZATION AND COSTS FOR A MEDICATION THERAPY MANAGEMENT (MTM) PROGRAM

    May 1, 2011, 00:00

  • PMH36 FACTORS ASSOCIATED WITH HEALTHCARE COSTS IN A POPULATION OF COMMERCIALLY INSURED CHILDREN AND ADOLESCENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORBIDITIES

    May 1, 2011, 00:00

  • PSY46 DISEASE SYMPTOMS, TREATMENT SATISFACTION, AND COPING STRATEGIES IN PATIENTS WITH LUPUS

    May 1, 2011, 00:00

  • DU2 PREVALENCE AND PREDICTORS OF POTENTIALLY SIGNIFICANT DRUG-DRUG INTERACTIONS IN THE ELDERLY

    May 1, 2011, 00:00

  • PCN109 TREATMENT PATTERNS AND HEALTHCARE RESOURCE UTILIZATION OF METASTATIC PROSTATE CANCER PATIENTS BY PHYSICIAN SPECIALTY

    May 1, 2011, 00:00

  • PCV96 TREND IN THE UTILIZATION OF PHARMACOLOGICAL AND NON-PHARMACOLOGICAL TREATMENT STRATEGIES IN THE MANAGEMENT OF NEWLY DIAGNOSED ATRIAL FIBRILLATION PATIENTS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMH12 THE PROFILE OF IMPAIRMENTS TO ATTENTION AND EPISODIC RECOGNITION MEMORY IN MILD COGNITIVE IMPAIRMENT AND ALZHEIMER'S DISEASE

    May 1, 2011, 00:00

  • PMH25 CLINICAL OUTCOMES AND ECONOMIC COSTS OF SECOND-GENERATION ANTIPSYCHOTICS IN PATIENTS WITH CHRONIC SCHIZOPHRENIA OR SCHIZOAFFECTIVE DISORDERS

    May 1, 2011, 00:00

  • PRS41 A REAL-WORLD EVALUATION OF BETA AGONIST USE DURING HOSPITALIZATIONS FOR COPD

    May 1, 2011, 00:00

  • PND5 ASSESSMENT OF PARKINSON'S DISEAES PROGRESSION RATES BY STAGE OF DISEASE

    May 1, 2011, 00:00

  • PCV85 TREATMENT FOR DEPRESSION IN WOMEN WITH HYPERTENSION

    May 1, 2011, 00:00

  • PHP110 BIOSIMILARS LITERATURE REVIEW- THE CURRENT LANDSCAPE AND IMPLICATIONS OF RECENT HEALTH CARE LEGISLATION FOR THE UNITED STATES MARKET

    May 1, 2011, 00:00

  • PMS71 COMPARISON OF PROPENSITY SCORE MATCHING AND INSTRUMENTAL VARIABLE METHODS WHEN ESTIMATING HEALTH CARE COSTS OF RHEUMATOID ARTHRITIS PATIENTS

    May 1, 2011, 00:00

  • PIH34 IMPLEMENTATION OF A STATE MEDICAID PRESCRIPTION CAP POLICY- IS THERE AN IMPACT ON BENEFICIARIES' MEDICAL SERVICES UTILIZATION AND COSTS?

    May 1, 2011, 00:00

  • PCV59 PERSISTENCE AND COMPLIANCE IN HYPERTENSIVE PATIENTS TREATED WITH FIXED OR UNFIXED COMBINATIONS OF ANGIOTENSIN RECEPTOR BLOCKERS, AMPLODIPINE AND HYDROCHLOROTHIAZIDE

    May 1, 2011, 00:00

  • PND21 ESTIMATED COSTS OF FINGOLIMOD MONITORING FOR INDIVIDUALS WITH RELAPSING REMITTING MULTIPLE SCLEROSIS

    May 1, 2011, 00:00

  • PSY19 THE COST-EFFECTIVENESS OF BORTEZOMIB PLUS MELPHALAN AND PREDNISONE VERSUS LENALIDOMIDE PLUS MELPHALAN AND PREDNISONE WITH CONTINUOUS LENALIDOMIDE MAINTENANCE TREATMENT FOR THE INITIAL TREATMENT OF MULTIPLE MYELOMA IN THE UNITED STATES ...

    May 1, 2011, 00:00

  • PSS16 DEVELOPMENT OF A DISEASE SPECIFIC VERSION OF THE EQ-5D FOR USE IN PSORIASIS

    May 1, 2011, 00:00

  • PMD16 COMPARISON OF COST AND CLINICAL OUTCOMES OF OPEN VERSUS LAPAROSCOPIC THORACIC PROCEDURES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PHP16 ANALYZING THE EUROPEAN EXTERNAL REFERENCE PRICING SYSTEM USING SPECTRAL GRAPH THEORY

    May 1, 2011, 00:00

  • PRM13 COMPARISON OF DISCRETE EVENTS SIMULATION SOFTWARE FOR USE IN HEALTH ECONOMICS OUTCOMES RESEARCH

    May 1, 2011, 00:00

  • PRM39 LITERATURE REVIEW OF RANDOMIZED, CONTROLLED STUDIES OF THE IMPACT OF PHARMACISTS' INTERVENTIONS TO IMPROVE PATIENT OUTCOMES

    May 1, 2011, 00:00

  • PDB76 DESIGNING A SERVICE FRAMEWORK FOR ELECTRONIC PERSONAL HEALTH RECORDS- A PATIENT-CENTRED APPROACH

    May 1, 2011, 00:00

  • PSY69 MODELING THE IMPACT OF REFILL OR ADMINISTRATION GAPS ON PATIENT DRUG LEVELS OF THE TNF-ALPHA INHIBITORS ETANERCEPT AND INFLIXIMAB

    May 1, 2011, 00:00

  • PRS35 PHARMACY QUALITY INDICATORS USING MISSISSIPPI MEDICAID- TESTING PQA-ENDORSED STARTER SET MEASURES AND 2010 TEST MEASURES

    May 1, 2011, 00:00

  • MC2 ASSESSING PREDICTORS OF MEDICATION ADHERENCE IN UNCONDITIONAL QUANTILE REGRESSION FRAMEWORK

    May 1, 2011, 00:00

  • PGI16 RESOURCE UTILIZATION AND HEALTH CARE COSTS ASSOCIATED WITH DIVERTICULAR DISEASE- RESULTS FROM A RETROSPECTIVE CLAIMS DATABASE ANALYSIS IN THE UNITED STATES

    May 1, 2011, 00:00

  • PMS19 FRACTURE-RELATED TREATMENT COSTS ATTRIBUTABLE TO PROTON PUMP INHIBITOR USE IN OSTEOPOROSIS PATIENTS

    May 1, 2011, 00:00

  • IN3 COSTS ASSOCIATED WITH HCV AND RELATED COMPLICATIONS IN THE UNITED STATES FROM A MANAGED CARE PAYER'S PERSPECTIVE

    May 1, 2011, 00:00

  • PCV108 CARDIOVERSION TREATMENT PATTERNS AND OUTCOMES AMONG ACUTE ATRIAL FIBRILLATION PATIENTS IN 5 EUROPEAN COUNTRIES

    May 1, 2011, 00:00

  • PRM38 THE EXTENSION OF THE COST-EFFECTIVENESS ACCEPTABILITY CURVE- HOW TO MAKE IT MORE INFORMATIVE?

    May 1, 2011, 00:00

  • PIN32 PHARMACOECONOMIC ANALYSIS OF MARAVIROC IN TREATMENT-EXPERIENCED HIV PATIENTS IN BRAZIL

    May 1, 2011, 00:00

  • PND46 THE IMPACT OF EPILEPSY ON ADULT AND PAEDIATRIC PATIENT'S LIVES- A CONCEPTUAL MODEL

    May 1, 2011, 00:00

  • PCN101 HEALTH CARE RESOURCE UTILIZATION AND ECONOMIC BURDEN OF METASTATIC AND RECURRENT LOCALLY-ADVANCED HEAD AND NECK CANCER PATIENTS

    May 1, 2011, 00:00

  • PCN78 THE DEVELOPMENT OF A VALUE BASED PRICING INDEX FOR NEW DRUGS IN METASTATIC COLORECTAL CANCER

    May 1, 2011, 00:00

  • PCV80 MEDICATION THERAPY MANAGEMENT IMPROVES HEALTH CARE UTILIZATION AND COSTS FOR EMPLOYERS

    May 1, 2011, 00:00

  • PMH60 BIPOLAR DISORDER RESULTS IN SIGNIFICANT BURDEN ON CAREGIVERS- ANALYSIS OF DATA FROM A LARGE MULTINATIONAL LONGITUDINAL STUDY (WAVE-BD)

    May 1, 2011, 00:00

  • MD4 EVALUATION OF AN INTERVENTION TO REDUCE POLY-PHARMACY IN MEDICARE PART D

    May 1, 2011, 00:00

  • PDB67 IT PROCESSES IN CLINICAL PRACTICES FOR DIABETES PATIENTS TYPE II

    May 1, 2011, 00:00

  • PSU12 IMMUNOSUPPRESSANT THERAPY ADHERENCE AND REJECTION OUTCOMES IN LIVER AND KIDNEY TRANSPLANT PATIENTS

    May 1, 2011, 00:00

  • PCN129 USE OF ELECTRONIC MEDICAL RECORDS (EMR) FOR ONCOLOGY OUTCOMES RESEARCH- ASSESSING THE COMPARABILITY OF EMR INFORMATION TO PATIENT REGISTRY AND HEALTH CLAIMS DATA

    May 1, 2011, 00:00

  • PRS46 MEASUREMENT COMPARABILITY BETWEEN PAPER AND ALTERNATE VERSIONS- RECOMMENDED ASSESSMENT STEPS USING THE LUNG FUNCTION QUESTIONNAIRE AS AN EXAMPLE

    May 1, 2011, 00:00

  • PMS9 COST CONSEQUENCE OF COLCHICINE APPROVAL IN THE MEDICAID PROGRAMS IN THE UNITED STATES

    May 1, 2011, 00:00

  • QA4 IS THE AIM OF THE HEALTH CARE SYSTEM TO MAXIMISE QALYS? AN INVESTIGATION OF ‘WHAT ELSE MATTERS’ IN THE NHS

    May 1, 2011, 00:00

  • PRS1 SEVERE ASTHMA EXACERBATIONS ASSOCIATED WITH LONG-ACTING BETA AGONISTS AMONG CHILDREN AND ADOLESCENTS WITH ASTHMA

    May 1, 2011, 00:00

  • PCN37 ESTIMATING COST OF TREATMENT IN ELDERLY PATIENTS WITH COLORECTAL CANCER USING MEDICARE DATA

    May 1, 2011, 00:00

  • PMH8 EFFECT OF VARIOUS ANTIDEPRESSANT GROUPS ON BONE MINERAL DENSITY (BMD)

    May 1, 2011, 00:00

  • PSY30 A REAL-WORLD EVALUATION OF ADHERENCE AND PERSISTENCE OF WEIGHT-LOSS PHARMACOTHERAPY IN THE UNITED STATES- 2007-2010

    May 1, 2011, 00:00

  • PMS40 HOW DOES OSTEOARTHRITIS SEVERITY INFLUENCE PATIENT PREFERENCES AND WILLINGNESS TO PAY FOR OSTEOARTHRITIS TREATMENTS?

    May 1, 2011, 00:00

  • PHP94 THE ROLE OF HEALTH-RELATED QUALITY OF LIFE DATA IN THE DRUG APPROVAL PROCESSES IN THE UNITED STATES AND EUROPE- A REVIEW OF GUIDANCE DOCUMENTS AND AUTHORIZATIONS OF MEDICINAL PRODUCTS FROM 2006 TO 2010

    May 1, 2011, 00:00

  • PMH61 NATIONAL ESTIMATES AND CHARACTERISTICS OF AMBULATORY CARE VISITS FOR DEMENTIA CARE IN THE UNITED STATES, 1998–2007

    May 1, 2011, 00:00

  • PCN106 RESEARCH ON THE FACTORS AFFECTING THE ADOPTION OF HIGH VALUE MEDICAL CONSUMES IN LESS DEVELOPED AREAS OF CHINA

    May 1, 2011, 00:00

  • PND1 PRESCRIBING PATTERNS OF DRUGS HAVING ANTICHOLINERGIC ACTIVITY IN PATIENTS WITH ALZHEIMER'S DISEASE

    May 1, 2011, 00:00

  • PDB3 LONG-TERM ANTIPROTEINURIC EFFECT OF ALISKIREN IN DIABETIC PATIENTS WITH PERSISTENT ALBUMINURIA DESPITE CHRONIC ACEI OR ARB TREATMENT

    May 1, 2011, 00:00

  • PGI3 THE LIKELIHOOD OF HAVING FUNCTIONAL DYSPEPSIA BASED ON OTHER COMORBID CONDITIONS

    May 1, 2011, 00:00

  • PGI2 PREDICTORS OF PROTON PUMP INHIBITOR (PPI) DOSING REGIMEN AMONG PATIENTS WITH GASTROESOPHAGEAL REFLUX DISEASE (GERD)

    May 1, 2011, 00:00

  • PCN124 CLINICAL AND DEMOGRAPHIC CHARACTERISTICS OF CHRONIC MYELOGENOUS LEUKEMIA PATIENTS TREATED AT PUBLIC ONCOLOGY CLINICS IN SÃO PAULO, BRAZIL

    May 1, 2011, 00:00

  • PHP85 APPLYING FUZZY MULTIPLE CRITERIA DECISION MAKING TO ESTABLISH A NEW HEALTH TECHNOLOGY ASSESSMENT SYSTEM WITH COVERAGE IMPLICATIONS IN TAIWAN NATIONAL HEALTH INSURANCE

    May 1, 2011, 00:00

  • PUK8 KIT73 STUDY- DOES TYPE OF DONOR INFLUENCE LONG-TERM COSTS OF CARE? RESULTS FROM POST-KIDNEY TRANSPLANT PATIENTS IN THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM (SUS)

    May 1, 2011, 00:00

  • PMH21 DIFFERENCES IN DAILY AVERAGE CONSUMPTION AND DAILY COSTS OF DESVENLAFAXINE, VENLAFAXINE XR, DULOXETINE, AND ESCITALOPRAM AMONG COMMERCIALLY INSURED PATIENTS

    May 1, 2011, 00:00

  • PMS51 RACIAL DISPARITIES IN UTILIZATION OF BIOLOGIC AND DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN A CALIFORNIA MEDICAID POPULATION WITH RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PDB32 ECONOMIC EVALUATION OF RANIBIZUMAB FOR THE TREATMENT OF DIABETIC MACULAR EDEMA IN CANADA

    May 1, 2011, 00:00

  • PMH29 ESTIMATION OF DIRECT COSTS OF TREATING SCHIZOPHRENIA FOR COMMUNITY-DWELLING UNITED STATES RESIDENTS

    May 1, 2011, 00:00

  • PSU15 DEVELOPMENT OF THE BARIATRIC AND OBESITY SPECIFIC SURVEY (BOSS)

    May 1, 2011, 00:00

  • PCN48 IMPACT ON HOSPITAL OUTPATIENT VISIT COSTS BY INITIATING PALONOSETRON VERSUS OTHER 5-HYDROXYTRYPTAMINE3 RECEPTOR ANTAGONISTS FOR PREVENTION OF CHEMOTHERAPY INDUCED NAUSEA AND VOMITING (CINV) AMONG PATIENTS WITH CANCER

    May 1, 2011, 00:00

  • PCV38 POTENTIAL ECONOMIC IMPACT OF DYSPNEA ASSOCIATED WITH TICAGRELOR USE

    May 1, 2011, 00:00

  • PIN39 IMMUNIZATION BARRIERS AND SUGGESTED SOLUTIONS IN IRAQ

    May 1, 2011, 00:00

  • PMD21 IS CYBERKNIFE A COST-EFFECTIVE OPTION FOR TREATING PROSTATE CANCER?

    May 1, 2011, 00:00

  • MC3 IMPACT OF MULTIPLE MEDICATION COMPLIANCE ON CARDIOVASCULAR OUTCOMES IN PATIENTS WITH TYPE II DIABETES AND COMORBID HYPERTENSION CONTROLLING FOR ENDOGENEITY BIAS

    May 1, 2011, 00:00

  • CN1 MONOTHERAPY OF ANDROGEN DEPRIVATION THERAPY VERSUS RADICAL PROSTATECTOMY AMONG VETERANS WITH LOCALIZED PROSTATE CANCER- A COMPARATIVE EFFECTIVENESS ANALYSIS OF RETROSPECTIVE COHORTS

    May 1, 2011, 00:00

  • PHP99 WILL BIOPHARMACEUTICAL INNOVATION STILL BE A PICTURE OF HEALTH AFTER IMPLEMENTATION OF HEALTH CARE REFORM?

    May 1, 2011, 00:00

  • PCV102 COMPLICATIONS ARISING DURING HOSPITALIZATION FOR HEMORRHAGIC OR ISCHEMIC STROKE- EVIDENCE FROM A LARGE ADMINISTRATIVE DATABASE

    May 1, 2011, 00:00

  • PMS72 SUITABILITY OF THE EFFICIENCY FRONTIER APPROACH FOR THE EVALUATION OF BIOLOGICAL AGENTS IN THE TREATMENT OF EARLY RHEUMATOID ARTHRITIS

    May 1, 2011, 00:00

  • PCV29 IMPROVING BLEEDING RISK ASSESSMENT FOR ANTICOAGULANT USE IN ATRIAL FIBRILLATION

    May 1, 2011, 00:00

  • MD3 EVALUATING THE WILLINGNESS-TO-PAY OF MEDICARE BENEFICIARIES FOR PART D PLAN ASSISTANCE

    May 1, 2011, 00:00

  • PCV56 COST-MINIMIZATION ANALYSIS OF LANDIOLOL FOR CT SCANNING FOR CVD SUSPICIOUS PATIENTS IN JAPAN

    May 1, 2011, 00:00

  • PUK13 COST-EFFECTIVENESS ANALYSIS OF THE EARLY CONVERSION OF TACROLIMUS TO MTOR INHIBITORS IN PATIENTS WITH RENAL TRANSPLANTATION

    May 1, 2011, 00:00

  • PMH33 THE EFFECTIVENESS OF BUPRENORPHINE-MEDICATION ASSISTED TREATMENT AMONG AETNA'S OPIOID DEPENDENT MEMBERS- AN ANALYSIS OF HEALTH CARE COSTS AND SERVICE UTILIZATION

    May 1, 2011, 00:00

  • PDB55 CLINICAL AND ECONOMIC EVALUATION OF A DIABETES MEDICATION MANAGEMENT PROGRAM- 2 YEAR PROGRAM UPDATE

    May 1, 2011, 00:00

  • PHP7 DEVELOPING PUBLIC HEALTH GUIDANCE - WHAT ARE THE DATA GAPS? REVIEW OF THE GAPS IN THE EVIDENCE IDENTIFIED BY NICE IN THE UNITED KINGDOM

    May 1, 2011, 00:00

  • PND19 HUMANISTIC AND ECONOMIC BURDEN IN TUBEROUS SCLEROSIS COMPLEX WITH NEUROLOGICAL MANIFESTATIONS- SYSTEMATIC REVIEW

    May 1, 2011, 00:00

  • PCN52 WILLINGNESS TO PAY AND COST BENEFIT ANALYSIS OF DELIVERY METHODS FOR DECISION SUPPORT FOR RURAL CANCER PATIENTS

    May 1, 2011, 00:00

  • PMH72 ANTIDEPRESSANT PERSISTENCE AND ASSOCIATED HEALTH CARE EXPENDITURES IN CHILDREN WITH DEPRESSION

    May 1, 2011, 00:00

  • PDB44 A NOVEL APPROACH FOR NON-ADHERENCE MEASUREMENT BASED ON PRESCRIPTION DATA- THE EXAMPLE OF ORAL DIABETICS IN THE THERAPY OF TYPE-2 DIABETES MELLITUS PATIENTS

    May 1, 2011, 00:00

  • PHP23 THE IMPACT OF MEDICARE PART D ON PRESCRIPTION VOLUME AND OUT-OF-POCKET COSTS OF MEDICALLY NECESSARY DRUGS

    May 1, 2011, 00:00

  • PDB57 IMPACT OF A PHARMACIST-BASED DIABETES MANAGEMENT PROGRAM ON ADHERENCE TO MEDICATION FOR DIABETIC PATIENTS

    May 1, 2011, 00:00

  • PCV3 RISK OF HOSPITALIZATIONS FOR VENOUS THROMBOEMBOLISM IN ATYPICAL VERSUS TYPICAL ANTIPSYCHOTIC USERS IN A NATIONAL SAMPLE OF MEDICARE BENEFICIARIES- A CLAIMS DATA ANALYSIS

    May 1, 2011, 00:00

  • PHP57 PATTERNS OF INSURANCE COVERAGE IN THE UNITED STATES- ANALYSIS OF THE 2004-2007 MEDICAL EXPENDITURE PANEL SURVEYS (MEPS)

    May 1, 2011, 00:00

  • PCN9 VALUE OF RESEARCH ANALYSES IN RESEARCH PRIORITIZATION OF CANCER GENOMIC APPLICATIONS

    May 1, 2011, 00:00

  • PCN112 COMPARISON OF CHARACTERISTICS OF COLORECTAL CANCER PATIENTS ADMITTED EMERGENTLY, URGENTLY OR ELECTIVELY IN WEST VIRGINIA HOSPITALS BETWEEN 2003-2007

    May 1, 2011, 00:00

  • EV3 A COMPARATIVE EFFECTIVENESS INDEX TO INFORM CLINICAL DECISIONS

    May 1, 2011, 00:00

  • PND37 INVESTIGATION OF THE PSYCHOMETRIC PROPERTIES OF THE SHORT PARKINSON'S EVALUATION SCALE/SCALES FOR OUTCOMES IN PARKINSON'S DISEASE (SPES/SCOPA)

    May 1, 2011, 00:00

  • PHP63 WHAT INFLUENCES PHARMACEUTICAL REIMBURSEMENT DECISIONS? A SYSTEMATIC REVIEW OF FACTORS REPORTED TO INFLUENCE DECISIONS IN OECD COUNTRIES

    May 1, 2011, 00:00

  • PCN93 ATTACHMENT STYLE AND HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH PROSTATE CANCER

    May 1, 2011, 00:00

  • DM1 IMPACT OF A PHARMACY REFILL MANAGEMENT SYSTEM ON OUTCOMES IN END STAGE RENAL DISEASE (ESRD) PATIENTS

    May 1, 2011, 00:00

  • PUK22 LEVELING THE PLAYING FIELD- A CASE STUDY ON TECHNICAL PRECISION IN COMPARATIVE EFFECTIVENESS RESEARCH FOR CLINICALLY LOCALIZED PROSTATE CANCER (PC)

    May 1, 2011, 00:00

  • PSY57 DOES CLINICAL DIAGNOSIS OF OBESITY INCREASE THE LIKELIHOOD OF RECEIVING OBESITY RELATED COUNSELING? A 2005-2008 NAMCS-NHAMCS ANALYSIS

    May 1, 2011, 00:00

  • PHP105 HOW ARE COVERAGE DECISIONS MADE IN PUBLICLY FUNDED HEALTH CARE PROGRAMS IN LOW- AND MIDDLE-INCOME COUNTRIES?

    May 1, 2011, 00:00

  • PDB73 A CLAIMS-BASED EMPIRIC APPROACH TO ASSESSING MEDICATION POSSESSION FOR PATIENTS INITIATING THERAPY WITH INSULINS

    May 1, 2011, 00:00

  • PDB47 NATIONAL IMPACT OF HEALTH CARE ACCESS ON HEALTH-RELATED QUALITY OF LIFE OF PATIENTS WITH DIABETES IN THE UNITED STATES

    May 1, 2011, 00:00

  • PIH43 METHODOLOGY TO IDENTIFY IN-VITRO FERTILIZATION PATIENTS USING A NATIONAL MANAGED CARE DATABASE

    May 1, 2011, 00:00

  • Editorial Board

    Mar 1, 2011, 00:00

  • Model Averaging in the Presence of Structural Uncertainty about Treatment Effects- Influence on Treatment Decision and Expected Value of Information

    Mar 1, 2011, 00:00

  • Improvements in Participation in Usual Daily Activities in Patients with Rheumatoid Arthritis Treated with Abatacept

    Mar 1, 2011, 00:00

  • Development of a Conceptual Framework and Calibrated Item Banks to Measure Patient-Reported Dyspnea Severity and Related Functional Limitations

    Mar 1, 2011, 00:00

  • Copyright/Subscription

    Mar 1, 2011, 00:00

  • Cost-Effectiveness of White Blood Cell Growth Factor Use among a Large Nationwide Cohort of Elderly Non-Hodgkin's Lymphoma Patients Treated with Chemotherapy

    Mar 1, 2011, 00:00

  • EQ-5D as a Quality of Life Measure in People with Dementia and Their Carers- Evidence and Key Issues

    Mar 1, 2011, 00:00

  • Cost-Effective Psychotherapy for Personality Disorders in The Netherlands- The Value of Further Research and Active Implementation

    Mar 1, 2011, 00:00

  • Cost-Effectiveness of Transdermal Nitroglycerin Use for Preterm Labor

    Mar 1, 2011, 00:00

  • The Time-Dependent Bias and its Effect on Extra Length of Stay due to Nosocomial Infection

    Mar 1, 2011, 00:00

  • Trajectory Classes of Decline in Health-Related Quality of Life in Parkinson's Disease- A Pilot Study

    Mar 1, 2011, 00:00

  • Imputing QALYs from Single Time Point Health State Descriptions on the EQ-5D and the SF-6D- A Comparison of Methods for Hepatitis A Patients

    Mar 1, 2011, 00:00

  • Estimation of Quality-Adjusted Life Expectancy in Patients Under Prolonged Mechanical Ventilation

    Mar 1, 2011, 00:00

  • Predicting EQ-5D Values Using the SGRQ

    Mar 1, 2011, 00:00

  • Health Dynamics- Implications for Efficiency and Equity in Priority Setting

    Mar 1, 2011, 00:00

  • Treatment with Inhaled Mometasone Furoate Reduces Short-Acting β2 Agonist Claims and Increases Adherence Compared to Fluticasone Propionate in Asthma Patients

    Mar 1, 2011, 00:00

  • Instructions for Authors

    Mar 1, 2011, 00:00

  • An Economic Evaluation of Short-Acting Opioids for Treatment of Breakthrough Pain in Patients with Cancer

    Mar 1, 2011, 00:00

  • Cost-Utility of Laparoscopic Nissen Fundoplication versus Proton Pump Inhibitors for Chronic and Controlled Gastroesophageal Reflux Disease- A 3-Year Prospective Randomized Controlled Trial and Economic Evaluation

    Mar 1, 2011, 00:00

  • Internet-Based Follow-Up Questionnaire for Measuring Patient-Reported Outcome after Total Hip Replacement Surgery—Reliability and Response Rate

    Mar 1, 2011, 00:00

  • How Valuable are Multiple Treatment Comparison Methods in Evidence-Based Health-Care Evaluation?

    Mar 1, 2011, 00:00

  • Health Care Use and Primary Prophylaxis with Colony-Stimulating Factors

    Mar 1, 2011, 00:00

  • Cost-Effectiveness of Sacral Neuromodulation Compared to Botulinum Neurotoxin A or Continued Medical Management in Refractory Overactive Bladder

    Mar 1, 2011, 00:00

  • Health-Related Quality of Life after Total Knee Replacement or Unicompartmental Knee Arthroplasty in an Urban Asian Population

    Mar 1, 2011, 00:00

  • Brief, Valid Measures of Dyspnea and Related Functional Limitations in Chronic Obstructive Pulmonary Disease (COPD)

    Mar 1, 2011, 00:00

  • Table of Contents

    Mar 1, 2011, 00:00

  • Cost-effectiveness analysis of LHRH agonists in the treatment of metastatic prostate cancer in Italy

    Jan 1, 2011, 00:00

  • Cost-effectiveness of infliximab for the treatment of active and progressive psoriatic arthritis

    Jan 1, 2011, 00:00

  • Preventable hospital admissions related to medication (HARM)- Cost analysis of the HARM study

    Jan 1, 2011, 00:00

  • Metric properties of the MacDQoL, individualized macular-disease-specific quality of life instrument, and newly identified subscales in French, German, Italian, and American populations

    Jan 1, 2011, 00:00

  • The CHD challenge- Comparing four cost-effectiveness models

    Jan 1, 2011, 00:00

  • Valuing pharmacogenetic testing services- A comparison of patients' and health care professionals' preferences

    Jan 1, 2011, 00:00

  • Table of contents

    Jan 1, 2011, 00:00

  • Reconsidering the value of rehabilitation for patients with cerebrovascular disease in Japanese acute health care hospitals

    Jan 1, 2011, 00:00

  • The economic burden of Medicare-eligible patients by multiple sclerosis type

    Jan 1, 2011, 00:00

  • Uncertainty analysis is inherently Bayesian—Reply to letter to the editor by John Stevens

    Jan 1, 2011, 00:00

  • Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of non–ST-segment elevation acute coronary syndromes

    Jan 1, 2011, 00:00

  • Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP)

    Jan 1, 2011, 00:00

  • Utility values in National Institute for Health and Clinical Excellence (NICE) Technology Appraisals

    Jan 1, 2011, 00:00

  • Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain

    Jan 1, 2011, 00:00

  • Is the Health Utilities Index 3 valid for patients with ankylosing spondylitis?

    Jan 1, 2011, 00:00

  • ISPOR code of ethics

    Jan 1, 2011, 00:00

  • Impact of ACE inhibitors on mortality and morbidity in patients with AMI- Does tissue selectivity matter?

    Jan 1, 2011, 00:00

  • Effect of subcutaneous methylnaltrexone on patient-reported constipation symptoms

    Jan 1, 2011, 00:00

  • Instructions for Authors

    Jan 1, 2011, 00:00

  • Incremental cost-effectiveness of various monthly doses of vardenafil

    Jan 1, 2011, 00:00

  • Copyright/Subscription

    Jan 1, 2011, 00:00

  • Screenee perception and health-related quality of life in colorectal cancer screening- A review

    Jan 1, 2011, 00:00

  • Can we account for selection bias? A comparison between bare metal and drug-eluting stents

    Jan 1, 2011, 00:00

  • Uncertainty analysis is inherently Bayesian

    Jan 1, 2011, 00:00

  • Valuing health across the lifespan- Health state preferences for seasonal influenza illnesses in patients of different ages

    Jan 1, 2011, 00:00

  • Exact method for computing absolute percent change in a dichotomous outcome from meta-analytic effect size- Improving impact and cost-outcome estimates

    Jan 1, 2011, 00:00

  • The use of instrumental variables- An alternative to traditional modeling?

    Jan 1, 2011, 00:00

  • Lung cancer treatment costs, including patient responsibility, by disease stage and treatment modality, 1992 to 2003

    Jan 1, 2011, 00:00

  • The value of budget impact analyses in evaluating targeted therapies—The case of RSV prophylaxis for preterm infants

    Jan 1, 2011, 00:00

  • The cost-utility analysis of adult male circumcision for prevention of heterosexual acquisition of HIV in men in sub-Saharan Africa- a probabilistic decision model

    Jan 1, 2011, 00:00

  • Estimating the Effect of Medication Adherence on Health Outcomes among Patients with Type 2 Diabetes—An Application of Marginal Structural Models

    Dec 1, 2010, 00:00

  • Methods for the Collection of Resource Use Data within Clinical Trials- A Systematic Review of Studies Funded by the UK Health Technology Assessment Program

    Dec 1, 2010, 00:00

  • Mixed Treatment Comparison Meta-Analysis Evaluating the Relative Efficacy of Nucleos(t)ides for Treatment of Nucleos(t)ide-Naive Patients with Chronic Hepatitis B

    Dec 1, 2010, 00:00

  • Network Meta-Analysis with Competing Risk Outcomes

    Dec 1, 2010, 00:00

  • Functional Impairment and Disability across Mood States in Bipolar Disorder

    Dec 1, 2010, 00:00

  • Cost-Effectiveness of Specialized Multidisciplinary Heart Failure Clinics in Ontario, Canada

    Dec 1, 2010, 00:00

  • Expanded HIV Screening in the United States- What Will It Cost Government Discretionary and Entitlement Programs? A Budget Impact Analysis

    Dec 1, 2010, 00:00

  • Data Generalizability, Data Transferability, and the Political Economy of Pharmacoeconomic Guidelines

    Dec 1, 2010, 00:00

  • Willingness to Pay for a Quality-Adjusted Life-Year- The Individual Perspective

    Dec 1, 2010, 00:00

  • Development of the EXAcerbations of Chronic Obstructive Pulmonary Disease Tool (EXACT)- A Patient-Reported Outcome (PRO) Measure

    Dec 1, 2010, 00:00

  • Cost–Utility Analysis of Tenofovir Disoproxil Fumarate in the Treatment of Chronic Hepatitis B

    Dec 1, 2010, 00:00

  • The Role of Observational Investigations in Comparative Effectiveness Research

    Dec 1, 2010, 00:00

  • Predicting Time Trade-Off Health State Valuations of Adolescents in Four Pacific Countries Using the Assessment of Quality-of-Life (AQoL-6D) Instrument

    Dec 1, 2010, 00:00

  • Discrete Choice Modeling for the Quantification of Health States- The Case of the EQ-5D

    Dec 1, 2010, 00:00

  • Use of a Disease-Specific Instrument in Economic Evaluations- Mapping WOMAC onto the EQ-5D Utility Index

    Dec 1, 2010, 00:00

  • Cost-Effectiveness of Maraviroc for Antiretroviral Treatment-Experienced HIV-infected Individuals in Mexico

    Dec 1, 2010, 00:00

  • The Value of Correcting Values- Influence and Importance of Correcting TTO Scores for Time Preference

    Dec 1, 2010, 00:00

  • Discrete Event Simulation- The Preferred Technique for Health Economic Evaluations?

    Dec 1, 2010, 00:00

  • How Is Evidence on Test Performance Synthesized for Economic Decision Models of Diagnostic Tests? A Systematic Appraisal of Health Technology Assessments in the UK Since 1997

    Dec 1, 2010, 00:00

  • What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?

    Dec 1, 2010, 00:00

  • Recent Trends and Geographic Patterns of the Burden of Disease Attributable to Smoking

    Dec 1, 2010, 00:00

  • Historical Lifetimes of Drugs in England- Application to Value of Information and Cost-Effectiveness Analyses

    Dec 1, 2010, 00:00

  • International Development of the Patient-Reported Outcome Indices for Multiple Sclerosis (PRIMUS)

    Dec 1, 2010, 00:00

  • Is Longer Waiting Time for Total Knee Replacement Associated with Health Outcomes and Medication Costs? Randomized Clinical Trial

    Dec 1, 2010, 00:00

  • Erratum

    Dec 1, 2010, 00:00

  • Economic Evaluations Alongside Effectiveness Trials

    Dec 1, 2010, 00:00

  • Reviewer Acknowledgment

    Dec 1, 2010, 00:00

  • PCN137 EMPLOYMENT STATUS AND WORK-RELATED DIFFICULTIES IN LUNG CANCER SURVIVORS COMPARED WITH GENERAL POPULATION

    Nov 1, 2010, 00:00

  • PHP24 CRITICAL ASSESSMENT OF BELGIAN REIMBURSEMENT DOSSIERS OF ORPHAN DRUGS

    Nov 1, 2010, 00:00

  • PIN36 ECONOMIC EVALUATION OF AZITHROMYCIN COMPARED WITH OTHER ANTIBIOTICS FOR COMMUNITY-ACQUIRED PNEUMONIA AND SINUSITIS TREATMENT

    Nov 1, 2010, 00:00

  • PMC52 TREATMENT SATISFACTION WITH MEDICATION- A REVIEW OF CONCEPTUAL FRAMEWORKS AND APPLICATIONS

    Nov 1, 2010, 00:00

  • PSY36 ASSESSING THE COST-EFFECTIVENESS OF PRIMARY PROPHYLAXIS FOR THE TREATMENT OF SEVERE HEMOPHILIA A

    Nov 1, 2010, 00:00

  • PHP123 PHARMACY NETWORK DEVELOPMENT DURING ECONOMIC TRANSITION IN POLAND

    Nov 1, 2010, 00:00

  • PCV135 CREATING AN EFFICIENT HOSPITAL PAYMENT SYSTEM

    Nov 1, 2010, 00:00

  • PSY20 SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) IS COSTLY FOR THE HEALTH CARE SYSTEM AND WORKPLACE- A SYSTEMATIC LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PDB73 THE PANORAMA PAN-EUROPEAN SURVEY- HYPOGLYCAEMIA ASSOCIATED WITH DIFFERENT PHARMACOLOGICAL TREATMENTS FOR TYPE 2 DIABETES

    Nov 1, 2010, 00:00

  • PHP34 PATIENT ACCESS TO INNOVATIVE MEDICINES IN HUNGARY

    Nov 1, 2010, 00:00

  • PRS44 EFFECTIVENESS AND EFFICIENCY OF ME-TOO LISTS AS ILLUSTRATED BY THE EXAMPLE OF INTRANASAL STEROIDS

    Nov 1, 2010, 00:00

  • PHP115 THE INCORPORATION OF ECONOMIC EVIDENCE IN THE DUTCH CLINICAL PRACTICE GUIDELINES

    Nov 1, 2010, 00:00

  • PSY68 HEPATITIS C-SPECIFIC QUALITY OF LIFE IS NOT PROPERLY MEASURED BY EXISTING INSTRUMENTS

    Nov 1, 2010, 00:00

  • PCN126 REVIEW OF PATIENT-REPORTED OUTCOMES IN PHASE II ONCOLOGY CLINICAL TRIALS

    Nov 1, 2010, 00:00

  • PMS67 CONJOINT ANALYSIS OF REDUCTION OF CO-PAYMENT RATE OF NATIONAL HEALTH INSURANCE SYSTEM IN JAPAN

    Nov 1, 2010, 00:00

  • PIN24 PATTERNS OF ANTIMICROBIAL DRUG USE IN INDIAN INTENSIVE CARE UNIT SETTINGS

    Nov 1, 2010, 00:00

  • PMC12 ASSESSMENT OF THE WORKLOAD REAL TIME DEDICATED TO EACH PATIENT IN INTENSIVE CARE UNITS (ICU)- PRELIMINARY RESULTS OF THE CRRA STUDY

    Nov 1, 2010, 00:00

  • PIN55 RISK SCORES PREDICTING RESOURCE USE OF HEPATITIS C PATIENTS IN GERMANY-AN ANALYSIS OF SICK FUND CLAIMS DATA

    Nov 1, 2010, 00:00

  • PIN11 COSTS OF QUANTIFERON TB-GOLD VERSUS TUBERCULIN SKIN TEST IN SPANISH HEALTH CARE WORKERS

    Nov 1, 2010, 00:00

  • PCN34 BUDGET IMPACT ANALYSIS OF CAPECITABINE IN ADJUVANT TREATMENT OF PATIENTS WITH RESECTED DUKESS PERSPECTIVES

    Nov 1, 2010, 00:00

  • PMS24 OSTEOPOROSIS COSTS IN ITALY. INTERIM RESULTS OF THE BLOCK STUDY

    Nov 1, 2010, 00:00

  • PIH64 A CONCEPTUAL FRAMEWORK FOR A PATIENT REPORTED OUTCOMES MEASURE OF ATTITUDES TOWARD COMPLEMENTARY AND ALTERNATIVE MEDICINE IN MENOPAUSE

    Nov 1, 2010, 00:00

  • PIH4 COMPARING THE MODEL PREDICTED VACCINE IMPACT AGAINST ROTAVIRUS HOSPITALIZATION WITH OBSERVED DATA IN BELGIUM

    Nov 1, 2010, 00:00

  • PMS47 COMPARISON OF DOSING PATTERNS BETWEEN FIBROMYALGIA PATIENTS WITH HIGH VERSUS LOW DULOXETINE OR PREGABALIN COMPLIANCE

    Nov 1, 2010, 00:00

  • PCN135 IMPROVEMENT IN QUALITY OF LIFE OUTCOMES IN INTERFERONALPHA TREATED PATIENTS COMPARED TO SUNITINIB IN ADVANCE OR METASTATIC RENAL CELL CARCINOMA

    Nov 1, 2010, 00:00

  • PMC57 BIAS IS WORSE THAN NOISE- HANDLING MISSING DATA FOR CONFOUNDERS IN OBSERVATIONAL STUDIES

    Nov 1, 2010, 00:00

  • PCN146 HEALTH RESOURCE UTILIZATION OF SUBJECTS RECEIVING DENOSUMAB AND ZOLEDRONIC ACID IN A RANDOMIZED PHASE 3 TRIAL OF ADVANCED BREAST CANCER PATIENTS WITH BONE METASTASES

    Nov 1, 2010, 00:00

  • PHP60 HEALTH INSURANCE SUBSIDY OF SPA TREATMENT IN HUNGARY

    Nov 1, 2010, 00:00

  • PCN157 REASONS FOR DISCONTINUATION OF HORMONAL THERAPY IN BREAST CANCER PATIENTS ACROSS FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PCN117 UTILITY ELICITATION STUDY IN THE UK GENERAL PUBLIC FOR LATE STAGE CHRONIC LYMPHOCYTIC LEUKEMIA

    Nov 1, 2010, 00:00

  • PHP93 DOES THE PACKAGE DESIGN MATTER? THE INFLUENCE OF OTC PACKAGE DESIGN ON PATIENTS DRUG KNOWLEDGE

    Nov 1, 2010, 00:00

  • PMC35 RECOMMENDATIONS ABOUT TRANSLATIONS IN THE FINAL FDA GUIDANCE ON PRO MEASURES-WHAT HAS CHANGED AND WHAT HAS REMAINED

    Nov 1, 2010, 00:00

  • PDB66 THE 8-ITEM MORISKY MEDICATION ADHERENCE SCALE MMAS- TRANSLATION AND VALIDATION STUDY OF THE MALAYSIAN VERSION

    Nov 1, 2010, 00:00

  • PSY4 COMPARATIVE COST-EFFECTIVENESS ANALYSES OF IRON CHELATING THERAPIES IN TRANSFUSION-DEPENDENT THALASSAEMIA POPULATION IN THAILAND

    Nov 1, 2010, 00:00

  • PIN12 COST-OF-ILLNESS OF CHRONIC HEPATITIS B INFECTION IN VIETNAM

    Nov 1, 2010, 00:00

  • PHP38 HOW EQUITABLE OF HEALTH SERVICE USE AND GOVERNMENT SUBSIDIES IN THAILAND AFTER ACHIEVING UNIVERSAL COVERAGE?

    Nov 1, 2010, 00:00

  • PDB38 ADDITION OF INCRETIN-THERAPY TO METFORMIN IN TYPE-2DIABETES MELLITUS (T2DM)- COST-EFFECTIVENESS OF LIRAGLUTIDE VERSUS SITAGLIPTIN FROM THE PERSPECTIVE OF THE GERMAN STATUTORY HEALTH INSURANCE (SHI)

    Nov 1, 2010, 00:00

  • PMC20 THE OPTIMAL NUMBER OF MONTE CARLO SIMULATIONS TO BE PERFORMED IN PROBABILISTIC SENSITIVITY ANALYSIS- EMPIRICAL EVIDENCE FROM ECONOMIC MODELS CONSTRUCTED FOR SUBMISSION TO THE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

    Nov 1, 2010, 00:00

  • PHP35 HEALTH TECHNOLOGY ASSESSMENTS- INDICATORS OF DEVELOPMENT IN ASIA

    Nov 1, 2010, 00:00

  • PHP97 TRAINING OF PHARMACEUTICAL SALES REPRESENTATIVES IN REGARD TO CHANGES IN HEALTH CARE POLICY IN GERMANY

    Nov 1, 2010, 00:00

  • PGI16 COST-EFFECTIVENESS OF ON-TREATMENT MONITORING OF HBSAG LEVELS TO PREDICT RESPONSE TO PEGINTERFERON-ALPHA-2A FOR HEPATITIS B TREATMENT UNDER THE PUBLIC PAYER PERSPECTIVE IN BRAZIL

    Nov 1, 2010, 00:00

  • PMC32 MINIMALLY IMPORTANT DIFFERENCE OF THE TREATMENT SATISFACTION WITH MEDICINES QUESTIONNAIRE (SATMED-Q)

    Nov 1, 2010, 00:00

  • PIN75 ESTIMATION OF PATIENTS WITH ANTIRETROVIRAL THERAPY POTENTIALLY USED FOR HIV PREVENTION (POST-EXPOSURE PROPHYLAXIS, MOTHER-TO-CHILD TRANSMISSION PROPHYLAXIS) IN GERMANY

    Nov 1, 2010, 00:00

  • PCN109 COMPARISON OF HOSPITALIZATION BURDEN BETWEEN METASTATIC AND NON-METASTATIC MELANOMA PATIENTS IN A US POPULATION

    Nov 1, 2010, 00:00

  • PHP46 COSTS OF TREATING TERMINAL PATIENTS IN DIFFERENT BELGIAN HEALTH CARE SETTINGS

    Nov 1, 2010, 00:00

  • PHP12 PHYSICIANS VIEWS ON BIOMEDICAL TECHNOLOGY IN GREECE

    Nov 1, 2010, 00:00

  • PCN60 CLINICAL AND ECONOMIC OUTCOMES ASSOCIATED WITH ADJUVANT CHEMOTHERAPY IN ELDERLY PATIENTS WITH EARLY STAGE OPERABLE BREAST CANCER

    Nov 1, 2010, 00:00

  • PND31 IMPACT OF AN ADHERENCE PROGRAM, RUN AS A TELEPHONE INTERVENTION ON COMPLIANCE WITH SUBCUTANEOUS INTERFERON -1A FOR MULTIPLE SCLEROSIS PATIENTS USING A MAIL-ORDER PHARMACY

    Nov 1, 2010, 00:00

  • PCV112 QUALITY OF LIFE AND DEPRESSION AMONG ADULTS WITH TYPE 2 DIABETES MELLITUS, HYPERTENSION, AND OBESITY

    Nov 1, 2010, 00:00

  • PMS68 PHYSICIANS STATED PREFERENCES OVER BENEFITS AND RISKS ASSOCIATED WITH NSAID USE IN PATIENTS WITH OSTEOARTHRITIS IN UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PMC7 TRANSLATING ITEM BANKS- BENEFITS AND CHALLENGES

    Nov 1, 2010, 00:00

  • PHP22 THE USE OF ECONOMIC EVALUATIONS IN DECISION-MAKING AT MACRO LEVEL- A LITERATURE REVIEW

    Nov 1, 2010, 00:00

  • PMH59 EVALUATION OF THE EFFECT OF ARIPIPRAZOLE ON QUALITY OF LIFE IN PATIENTS WITH SCHIZOPHRENIA IN A PROSPECTIVE, MULTICENTRE, OPEN-LABEL STUDY

    Nov 1, 2010, 00:00

  • PUK25 USING GENETIC POLYMORPHISM AS A STRATEGY TO ESTIMATE THE POTENTIAL COST-EFFECTIVENESS OF PHARMACOLOGICAL CCR5 BLOCKADE IN DIALYSIS PATIENTS

    Nov 1, 2010, 00:00

  • PCN75 COMPARISON OF ADVANCED NONINVASIVE TECHNIQUES TO SCREEN COLORECTAL CANCER- FECAL IMMUNOCHEMICAL TEST VS. FECAL DNA; A COS-EFFECTIVENESS STUDY

    Nov 1, 2010, 00:00

  • PCV24 AN EPIDEMIOLOGICAL EVALUATION OF THE IMPACT OF PERCUTANEOUS CORONARY INTERVENTIONS ON THE LENGTH OF STAY AND MORTALITY OF PATIENTS HOSPITALIZED WITH ACUTE CORONARY SYNDROMES

    Nov 1, 2010, 00:00

  • PSS10 CLINICAL AND COST-EFFECTIVENESS EVALUATION OF A LOW FRICTION AND SHEAR PRODUCT IN THE MANAGEMENT OF PATIENTS AT RISK OF SKIN BREAKDOWN WITHIN A HOSPITAL SETTING

    Nov 1, 2010, 00:00

  • PSY18 DIRECT MEDICAL COSTS OF LIQUID INTRAVENOUS IMMUNOGLOBULINS IN CHILDREN, ADOLESCENTS AND ADULTS IN SPAIN

    Nov 1, 2010, 00:00

  • PMS20 COST AND QUALITY OF LIFE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN SOUTH KOREA

    Nov 1, 2010, 00:00

  • PMC29 USING DOZENS OF ATTRIBUTES WITHOUT INCREASING RESPONDENT BURDEN- HOW TO ADAPT LATENT VARIABLE MODELING FOR LINKING ATTRIBUTES ON SEPARATE CONJOINT SURVEYS

    Nov 1, 2010, 00:00

  • PMS18 A BUDGET IMPACT MODEL FOR THE ECONOMIC ASSESSMENT OF TOCILIZUMAB IN THE TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS IN ITALY

    Nov 1, 2010, 00:00

  • PMH67 FACTORS ASSOCIATED WITH ANTIPSYCHOTICS USE AMONG COMMUNITY-DWELLING OLDER PERSONS WITH DEMENTIA

    Nov 1, 2010, 00:00

  • PDB32 COST-EFFECTIVENESS CONSEQUENCES OF OBESITY IN T2DM BY INSULIN ANALOGUE THERAPY

    Nov 1, 2010, 00:00

  • PMH65 EFFECTIVENESS OF PHARMACEUTICAL THERAPY OF ADHD (ATTENTION-DEFICIT/HYPERACTIVITY DISORDER) IN ADULTS-A HEALTH TECHNOLOGY ASSESSMENT

    Nov 1, 2010, 00:00

  • PSY34 COST-EFFECTIVENESS OF TAPENTADOL PROLONGED-RELEASE (PR) COMPARED TO OXYCODONE AND MORPHINE IN PATIENTS WITH CHRONIC MODERATE TO SEVERE NON-CANCER PAIN IN SWEDEN

    Nov 1, 2010, 00:00

  • PCV58 SUBSTITUTION INFLUENCE FROM MARK DRUGS TO GENERICS IN THE ARTERIAL HYPERTENSION THERAPEUTIC COMPLIANCE AND THE DYSLIPEMIA IN A POPULATION SETTING

    Nov 1, 2010, 00:00

  • PDB80 A CONTROLLED, PROSPECTIVE LONGITUDINAL, INTERVENTIONAL, NATURALISTIC STUDY TO EVALUATE THE UNIQUE HEALTH CARE PROGRAM 'CONVERSATION MAP' FOR TURKISH PATIENTS WITH TYPE-2 DIABETES IN ONE GERMAN MAJOR CITY

    Nov 1, 2010, 00:00

  • PCV48 ST. VINCENTS PRIVATE HOSPITAL VENOUS THROMBOEMBOLISM PREVENTION PROJECT- ANALYSIS OF REDUCED COST AND IMPROVED CLINICAL OUTCOMES

    Nov 1, 2010, 00:00

  • PUK24 A COST-UTILITY ANALYSIS OF CINACALCET IN SECONDARY HYPERPARATHYROIDISM (SHPT) IN FIVE EUROPEAN COUNTRIES

    Nov 1, 2010, 00:00

  • PCN16 MIXED TREATMENT COMPARISON OF BEVACIZUMAB-BASED THERAPIES RELATIVE TO DOUBLET-CHEMOTHERAPY COMBINATIONS TO ESTIMATE THE RELATIVE EFFICACY IN PROGRESSION-FREE SURVIVAL FOR TREATMENT OF FIRST-LINE ADVANCED OR METASTATIC NON-SMALL CELL L ...

    Nov 1, 2010, 00:00

  • PDB40 THE ECONOMIC IMPORTANCE OF 'METABOLIC MEMORY' IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) IN SWEDEN

    Nov 1, 2010, 00:00

  • PCN17 NO CONCLUSIVE EVIDENCE FROM RANDOMIZED CONTROLLED TRIALS (RCTS) FOR IMPROVED SURVIVAL WITH SECOND-LINE TREATMENT OPTIONS, IN PATIENTS WITH METASTATIC HORMONEREFRACTORY PROSTATE CANCER (MHRPC) PREVIOUSLY TREATED WITH DOCETAXEL

    Nov 1, 2010, 00:00

  • PHP75 EVALUATION OF THE IMPACT OF INPATIENT CLINICAL PHARMACY SERVICES ON THE QUALITY AND COST OF PHARMACOTHERAPY IN INTERNAL MEDICINE WARDS

    Nov 1, 2010, 00:00

  • PMC21 USING GROWTH IN THE COST-EFFECTIVENESS THRESHOLD TO INFORM THE DIFFERENTIAL BETWEEN THE DISCOUNT RATES ON COSTS AND HEALTH EFFECTS- REASON TO BE CAUTIOUS?

    Nov 1, 2010, 00:00

  • PIH39 PATIENTS WITH URINARY DISORDERS, EVOCATIVE OF BPH WHAT ARE THEIR EXPECTATIONS?

    Nov 1, 2010, 00:00

  • PMC11 ARE THRESHOLD RANGES FOR COST PER QALY A BARRIER TO RESEARCH FOR LIFE EXTENDING TREATMENTS

    Nov 1, 2010, 00:00

  • PSS32 THE EXPERIENCE OF EXTERNAL GENITAL WARTS AND GENITAL HERPES ON QUALITY OF LIFE

    Nov 1, 2010, 00:00

  • PSY10 CHARACTERIZATION OF TREATMENT STRATEGIES FOR NEUROPATHIC PAIN- EVIDENCE FROM A PAIN SPECIALIST SETTING IN THAILAND

    Nov 1, 2010, 00:00

  • PCV13 META REGRESSION ANALYSIS TO INDIRECTLY COMPARE THE SAFETY AND EFFICACY OF DALTEPARIN TO ENOXAPARIN FOR THE PREVENTION OF VENOUS THROMBOEMBOLIC EVENTS (VTES) IN TOTAL HIP REPLACEMENT (THR) SURGERY

    Nov 1, 2010, 00:00

  • PHP8 INTERVENTIONS TO REDUCE HOSPITAL READMISSIONS IN THE ELDERLY

    Nov 1, 2010, 00:00

  • PMC46 TRANSLATION AND LINGUISTIC VALIDATION OF PRO MEASURES- RESPONSE OPTION ISSUES

    Nov 1, 2010, 00:00

  • PCN149 DECIDING UPON NEW AND EXPENSIVE TECHNOLOGIES IN HEALTH CARE- REAL OPTIONS ANALYSIS IN PROTON THERAPY

    Nov 1, 2010, 00:00

  • PGI5 EVALUATION OF OCTREOTIDE COST AFTER PHARMACEUTICAL CARE IMPLEMENTATION AT SURGICAL WARD

    Nov 1, 2010, 00:00

  • PCN26 ESTIMATION OF THE EPIDEMIOLOGICAL EFFECT OF RITUXIMAB FOR THE TREATMENT OF AGGRESSIVE NON-HODGKIN LYMPHOMA

    Nov 1, 2010, 00:00

  • PCV18 COMPARISON OF MIXED DYSLIPIDEMIAS AMONG HIGH CARDIOVASCULAR RISK PRIMARY CARE PATIENTS- RESULTS OF A POOLED ANALYSIS OF PRIMULA DATA FROM CANADA, SPAIN, SWEDEN, AND THE UNITED KINGDOM

    Nov 1, 2010, 00:00

  • PIH10 COST-EFECTIVENESS OF QUADRIVALENT AND BIVALENT HPV VACCINATIONS AGAINST CERVICAL CANCER

    Nov 1, 2010, 00:00
  • «
  • 131
  • 132
  • 133 (current)
  • 134
  • 135
  • 136
  • 137
  • 138
  • 139
  • 140
  • »